Nature-Inspired Multifunctional Ligands: Focusing on Amyloid-Based Molecular Mechanisms of Alzheimer's Disease

被引:24
|
作者
Simoni, Elena [1 ]
Serafini, Melania M. [2 ]
Bartolini, Manuela [1 ]
Caporaso, Roberta [1 ]
Pinto, Antonella [2 ]
Necchi, Daniela [2 ]
Fiori, Jessica [1 ]
Andrisano, Vincenza [3 ]
Minarini, Anna [1 ]
Lanni, Cristina [2 ]
Rosini, Michela [1 ]
机构
[1] Univ Bologna, Dept Pharm & Biotechnol, Alma Mater Studiorum, Via Belmeloro 6, I-40126 Bologna, Italy
[2] Univ Pavia, Dept Drug Sci, Pharmacol Sect, Vle Taramelli 14, I-27100 Pavia, Italy
[3] Univ Bologna, Alma Mater Studiorum, Dept Life Qual Studies, Corso Augusto 237, I-47921 Rimini, Italy
关键词
Alzheimer's disease; antioxidants; amyloid-beta peptide; p53; multifunctional ligands; DOXORUBICIN INDUCES APOPTOSIS; TARGET-DIRECTED LIGANDS; OXIDATIVE STRESS; BETA-PEPTIDE; SYNAPTIC PLASTICITY; CASCADE HYPOTHESIS; PRECURSOR PROTEIN; THIOFLAVINE-T; CELL-DEATH; IN-VITRO;
D O I
10.1002/cmdc.201500422
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The amyloidogenic pathway is a prominent feature of Alzheimer's disease (AD). However, growing evidence suggests that a linear disease model based on beta-amyloid peptide (A beta) alone is not likely to be realistic, which therefore calls for further investigations on the other actors involved in the play. The pro-oxidant environment induced by A beta in AD pathology is well established, and a correlation among A beta, oxidative stress, and conformational changes in p53 has been suggested. In this study, we applied a multifunctional approach to identify allyl thioesters of variously substituted trans-cinnamic acids for which the pharmacological profile was strategically tuned by hydroxy substituents on the aromatic moiety. Indeed, only catechol derivative 3 [(S)-allyl(E)-3-(3,4-dihydroxyphenyl)prop-2-enethioate] inhibited A beta fibrilization. Conversely, albeit to different extents, all compounds were able to decrease the formation of reactive oxygen species in SH-SY5Y neuroblastoma cells and to prevent alterations in the conformation of p53 and its activity mediated by soluble sub-lethal concentrations of A beta. This may support an involvement of oxidative stress in A beta function, with p53 emerging as a potential mediator of their functional interplay.
引用
收藏
页码:1309 / 1317
页数:9
相关论文
共 50 条
  • [1] Amyloid-based interventions in Alzheimer's disease
    Kennedy, Gary J.
    Golde, Todd E.
    Tarlot, Pierre N.
    Cummings, Jeffrey L.
    [J]. CNS SPECTRUMS, 2007, 12 (01) : 1 - +
  • [2] Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics
    Selkoe, DJ
    Schenk, D
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2003, 43 : 545 - 584
  • [3] Amyloid-based approaches for the treatment of Alzheimer's disease
    Nitsch, R.
    Hock, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 6 - 6
  • [4] Clinical trials of amyloid-based therapies for Alzheimer's disease
    Tariot, Pierre N.
    [J]. CNS SPECTRUMS, 2007, 12 (01) : 7 - 10
  • [5] Alzheimer's disease: amyloid-based pathogenesis and potential therapies
    Zhou, Yixiu
    Sun, Yuhui
    Ma, Quan-Hong
    Liu, Yaobo
    [J]. CELL STRESS, 2018, 2 (07) : 150 - 161
  • [6] Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza, Francesco
    Logroscino, Giancarlo
    Imbimbo, Bruno P.
    Solfrizzi, Vincenzo
    [J]. CURRENT OPINION IN PSYCHIATRY, 2014, 27 (02) : 128 - 137
  • [7] Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease
    Kobayashi, DT
    Chen, KS
    [J]. GENES BRAIN AND BEHAVIOR, 2005, 4 (03) : 173 - 196
  • [8] Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
    Panza, Francesco
    Solfrizzi, Vincenzo
    Imbimbo, Bruno P.
    Tortelli, Rosanna
    Santamato, Andrea
    Logroscino, Giancarlo
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (03) : 405 - 419
  • [9] Progress in molecular mechanisms of β-amyloid peptides in Alzheimer's disease
    Sun Li-Wen
    Tang Syao-Wei
    Hu Ying-He
    [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2007, 34 (01) : 18 - 24
  • [10] Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
    Li, Yun
    Liu, Yahong
    Wang, Zhaojun
    Jiang, Yongjun
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (11) : 1515 - 1522